Pharma and Profits
eBook - ePub

Pharma and Profits

Balancing Innovation, Medicine, and Drug Prices

  1. English
  2. ePUB (mobile friendly)
  3. Available on iOS & Android
eBook - ePub

Pharma and Profits

Balancing Innovation, Medicine, and Drug Prices

About this book

High-level commentary on various facets of the pharmaceutical industry from a key leader in the field

This book clearly explains the value that the pharmaceutical industry offers to society which is often underreported against the more negative topic of high drug prices. It also offers an overview for drug discovery and development professionals, highlighting the challenges that such drug hunters should be aware of when developing new drugs. Case studies to illustrate topics like hepatitis C, mRNA vaccines, insulin, and price controls are included to aid in seamless reader comprehension.

Written by John LaMattina, former president of Pfizer Global Research and Development and well-known speaker and writer for the pharma industry, sample topics covered and questions explored within the work include:

  • Fiscal consequences of curing hepatitis C
  • mRNA vaccines and the race for a cure
  • Why the government does not deserve a piece of Biopharma's profits
  • Paying for drugs whose ultimate value is unknown
  • The impact of reduced revenues on R&D

This book is a must-read for biopharmaceutical professionals and executives who wish to gain high-level insight into key challenges that must be first understood, then overcome, within the pharmaceutical industry.

Frequently asked questions

Yes, you can cancel anytime from the Subscription tab in your account settings on the Perlego website. Your subscription will stay active until the end of your current billing period. Learn how to cancel your subscription.
No, books cannot be downloaded as external files, such as PDFs, for use outside of Perlego. However, you can download books within the Perlego app for offline reading on mobile or tablet. Learn more here.
Perlego offers two plans: Essential and Complete
  • Essential is ideal for learners and professionals who enjoy exploring a wide range of subjects. Access the Essential Library with 800,000+ trusted titles and best-sellers across business, personal growth, and the humanities. Includes unlimited reading time and Standard Read Aloud voice.
  • Complete: Perfect for advanced learners and researchers needing full, unrestricted access. Unlock 1.4M+ books across hundreds of subjects, including academic and specialized titles. The Complete Plan also includes advanced features like Premium Read Aloud and Research Assistant.
Both plans are available with monthly, semester, or annual billing cycles.
We are an online textbook subscription service, where you can get access to an entire online library for less than the price of a single book per month. With over 1 million books across 1000+ topics, we’ve got you covered! Learn more here.
Look out for the read-aloud symbol on your next book to see if you can listen to it. The read-aloud tool reads text aloud for you, highlighting the text as it is being read. You can pause it, speed it up and slow it down. Learn more here.
Yes! You can use the Perlego app on both iOS or Android devices to read anytime, anywhere — even offline. Perfect for commutes or when you’re on the go.
Please note we cannot support devices running on iOS 13 and Android 7 or earlier. Learn more about using the app.
Yes, you can access Pharma and Profits by John L. LaMattina in PDF and/or ePUB format, as well as other popular books in Business & Pharmaceutical, Biotechnology & Healthcare Industry. We have over one million books available in our catalogue for you to explore.

Information

Table of contents

  1. Cover
  2. Table of Contents
  3. Title Page
  4. Copyright Page
  5. Dedication
  6. ACKNOWLEDGMENTS
  7. INTRODUCTION
  8. CHAPTER 1: THE $1000 PILL
  9. CHAPTER 2: ENTER THE PAYERS
  10. CHAPTER 3: PANDEMIC
  11. CHAPTER 4: FEDERAL INVESTMENT IN R&D
  12. CHAPTER 5: INSULIN
  13. CHAPTER 6: THE COSTLY ALZHEIMER’S DISEASE DRUG
  14. CHAPTER 7: GENE THERAPY
  15. CHAPTER 8: PROVING THE VALUE OF EXPENSIVE DRUGS
  16. CHAPTER 9: GENERIC DRUGS
  17. CHAPTER 10: ABOUT THOSE SOARING PHARMA PROFITS
  18. CHAPTER 11: SCHEMES TO LOWER DRUG PRICES
  19. FINAL THOUGHTS
  20. Index
  21. End User License Agreement